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1. Introduction 
Recent studies of arachidonic acid metabolism in 
polymorphonuclear leukocytes have led to the dis- 
covery of the biologically active leukotrienes [ 11. The 
synthesis of these compounds is initiated by oxygena- 
tion of arachidonic acid at C-5 forming 5hydroperoxy- 
eicosatetraenoic acid [2], which is further converted 
to the unstable 5 ,6-epoxy-7,9,11 ,14-eicosatetraenoic 
acid (leukotriene &, LTA4) [3,4]. The epoxide is 
hydrolysed either enzymatically to SS,12R-dihydroxy- 
6_cis,8-rruns,lO-trans,l4_cis-eicosatetraenoic acid 
(LTB,) [S-7] or non-enzymatically to additional 
isomeric S,12- and 5,6-dihydroxy eicosatetraenoic 
acids [8]. LT& is also converted by addition of 
glutathione into LTC4 [9,10]. This compound and 
two metabolites, LTD4 and LTE4, are responsible for 
the biological activity of most preparations of slow- 
reacting substance of anaphylaxis (SRS-A) [ 11,121. 
We have reported that a new group of leukotrienes 
can also be formed by initial oxygenation at C-l 5 
[13,14]. 
Here, we describe the formation of 5S,12S- 
dihydroxy_6,8,10,14eicosatetraenoic acid and 
5S,12S,20-trihydroxy-6,8,10,14-eicosatetraenoic a id 
in preparations of human leukocytes. These novel 
metabolites are not formed via the leukotriene path- 
way. Instead arachidonic acid is transformed by a 
double oxygenation to the dihydroxy acid and fur- 
ther w oxidized to the trihydroxy acid. 
2. Materials and methods 
2.1. Materials 
Arachidonic acid was obtained from Nu-Check 
ElsevierlNorth-Holland Biomedical Press 
Prep. (Elysian MN) ionophore A23 187 from Calbio- 
them-Behring (La Jolla CA), Dextran T-500 from 
Pharmacia Fine Chemicals (Uppsala) and Silicar CC4 
from Mallinkrodt (St Louis MO). Ampulles of ‘*OZ 
(100 ml) were purchased from Miles Labs. (Elkhurt 
IN). 
2.2. Cell preparation and incubations 
Preparation of leukocyte suspensions from par- 
tially purified concentrates of human leukocytes 
(from the Karolinska Hospital, Stockholm) was per- 
formed as in [ 151. The cells (mainly neutrophil granu- 
locytes contaminated with platelets) were suspended 
in phosphate buffered saline (pH 7.4) (containing 
0.87 mM CaC12) to give final cont. 30-100 X lo6 
white cells/ml. Cell suspensions (200 ml) were pre- 
incubated at 37°C for 10 min. After addition of ion- 
ophore A23 187 and arachidonic acid (final cont. 5 
and 150 PM, respectively) the cells were incubated 
for 10 min and the incubations terminated by addi- 
tion of 3 vol. ethanol. 
2 3 . . Labeling experiments with Ia0 
Phosphate-buffered saline (90 m;> was introduced 
into a 3-necked round flask and the flask was evacu- 
ated and flushed with argon prior to introduction of 
“OZ. Finally, the system was brought to atmospheric 
pressure with argon and 6 X 10’ leukocytes in 10 ml 
phosphate-buffered saline were injected into the 
flask. Thereafter the cells were incubated with iono- 
phore A23 187 and arachidonic acid as above. 
2.4. Purification 
After filtration of precipitated material the filtrate 
was evaporated to remove the ethanol. The remaining 
water phase was extracted at pH 3 with diethyl ether 
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and the extract was purified on a silicic acid (Silicar 
CC-4) column eluted with diethyl ether/hexane, 
1 O/90 (v/v) and 40/60 (v/v) and methanol/ethyl ace- 
tate, 5/95 (v/v). The last fraction was subjected to 
reverse phase high performance liquid chromatog- 
raphy (BP-HPLC) using a Polygosil60-10 C r8 column 
(500 X 10 mm, Macherey Nagel, Dtiren) eluted with 
methanol/water/acetic acid, 70/30/0.01 (v/v/v) at 
4 ml/min. Eluted material was monitored with a 
W-detector at 270 nm. The compounds were con- 
verted to methyl esters by treatment with diazo- 
methane prior to straight phase (SP-)HPLC on a 
Nucleosil SO-5 column (250 X 4.6 mm, Macherey 
Nagel) using hexane/isopropyl alcohol/acetic acid 
95/5/0.01 (v/v/v) (dihydroxy acids), or 90/10/0.01 
(v/v/v) (trihydroxy acids) at a flow rate of 1 ml/min. 
2.5. Steric analysis of alcohol groups 
(-)-Menthoxycarbonyl derivatives, prepared as in 
[ 161, were purified on a RPHPLC column (Nucleosil 
5 CIs; 250 X 4.6 mm, Macherey Nagel) eluted with 
methanol/water, 97.5/2.5 (v/v) at 1 ml/min, dissolved 
in chloroform and subjected to oxidative ozonolysis 
[ 161. The short chain menthoxycarbonyl derivatives 
were treated with diazomethane prior to gas-chro- 
matographic analysis using a 3% OV-2 10 column (on 
Chromosorb W,HP). 
2.6. Gas chromatography-mass spectrometry 
fG@fS) 
Combined GC/MS was carried out on a LKB 
9000 S instrument with a 1% SE-30 (on Chromosorb 
W,HP) column at 235’C (ionizing voltage 22.5 eV). 
Mass spectra were recorded with a computer system 
as in [ 171. Methyl esters of the compounds were 
transformed into trimethylsilyl (MeaSi) ethers by 
treatment with hexamethyldisilazane and trimethyl- 
chlorosilane in pyridine. [‘Hra]MeaSi derivatives 
were prepared similarly using [‘Halhexamethyldi- 
silazane and [‘Hg] trimethylchlorosilane. Hydrogen- 
ated compounds were prepared using platinum oxide 
as catalyst [5]. 
3. Results 
Leukocyte suspensions were incubated with iono- 
phore A23 187 and arachidonic acid. The BP-HPLC 
chromatogram of the extracted and purified products 
was similar to those obtained with human peripheral 
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blood and rabbit peritoneal polymorphonuclear 
leukocytes (PMNL) [6,8]. The main dihydroxylated 
product formed in these systems had been described 
as LTB+ Eluted material corresponding to this peak 
and to a more polar peak (retention time 12 min) 
were collected separately and converted to methyl 
esters. 
Further purification of the less polar material on 
SP-HPLC resulted in the appearance of two separate 
main peaks (fig.1). Ultraviolet spectrometry of the 
major compound (A) showed absorption maximum 
at 268 nm with shoulders at 258 and 278 nm indicat- 
ing that the compound contained a conjugated triene 
structure. GC/MS of the trimethylsilyl ether methyl 
ester of compound A showed a peak with C-value 
22.4 (1% SE-30). The mass spectrum (fig.2) had prom- 
inent ions at m/e 494 (M), 479 (M-l 5) 463 (M-3 1), 
404 (M-90) 393 (M-101, loss of ‘CH-(CH2)2- 
COOCH& 383 (M-l 11, loss of ‘CH2-CH=CH- 
(CH2)4-CH3), 354 (probably ‘CH=CH-(CH=CH)z- 
C(OSiMe3)-(CH2)a-C(OCH3)=O’SiMe, from a 
rearrangement), 293 (M-( 111 t 90)) 279,213 
(MeaSiO’=CH-CH*--CH=CH-(CH2),-CH& 203 
(base peak; Me$iO+=CH-(CH2)a-COOCHa and 
Compound A 
I Compound B 
I I 1 1 . 
0 10 20 30 
Elution time tmln) 
Fig.1. The upper curve shows a SP-HPLC chromatogram of 
the methyl esters of the products corresponding to the main 
peak from RPRPLC. The lower curve shows a SP-HPLC 
chromatogram of the methyl esters of the two epimers (at 
C-12) of 5,12dihydroxyd-fmns,8-trans,lO-f~1s,l4ciseico- 
satetraenoic acid. 
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Fig.2. Mass spectrum of the Me,Si derivative of the methyl ester of compound A. 
M-(1 11 t 90 + 90)), 171 and 129. This suggests a Methyl esters of the polar products were further 
tetraunsaturated C-20 fatty acid structure with purified on SP-HPLC. The UV-spectrum of a main 
hydroxyl groups at C-5 and C-12. The structures of compound (C) was identical to that of compound A. 
the ions above were supported by the mass spectrum CC/MS of the MesSi derivative of the methyl ester of 
of the [2Hrs] trimethylsilyl ether methyl ester of compound C gave a peak with C-value 25.4. The mass 
compound A. The mass spectrum of the MeaSi deriva- spectrum (fig.3) contained ions of high intenstity at 
tive of the methyl ester of hydrogenated compound A m/e 582 (M), 567 (M-15) 551 (M-31) 492 (M-90) 
(C-value 24.0) was in complete agreement with the 481 (M-101, see above), 402 (M-(2 X 90)) 391 
reported mass spectrum of the same derivative of (M-(90 + 101)) 383 (M-l 99, loss of ‘CH2-CH= 
hydrogenated LTB4 [5]. The results strongly indi- CH-(CH2)4-CH20SiMea), 354 (see above), 301 
cated that compound A was a new isomer of 5,12- (MeaSiO+=CH-CH2-CH=CH-(CH2)4-CH20SiMea), 
dihydroxy_6,8,10,14_eicosatetraenoic a id. The UV- 203 (base peak; see above), 171 and 129. This indi- 
and CC/MS-data confirmed that the minor compound cates a tetraunsaturated C-20 structure with three 
(B) was LTB4 since the results obtained correspond hydroxyl groups, located at C-5, C-12 and the third 
to those described for that compound [5]. at a position beyond C-l 3. The relative high intensity 
5 
a 204 129 
in 
Fig.3. Mass spectrum of the Me,Si derivative of the methyl ester of compound C. 
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Fig.4. Mass spectrum of the Me,% derivative of the methyl ester of hydrogenated compound C. 
of ions at m/e 203,301 (i.e., 213 t 88) and 354 indi- 
cate that compound C is structurally related to com- 
pound A (c.f., fig.2). Evidence for an 01 hydroxyla- 
tion was obtained from the equivalent chain length 
(C-25.4) which was increased with 3.0 C [18,19] as 
compared to the C-value of compound A (C-22.4). 
Thus, the indicated structure of 5,12,20Uhydroxy- 
6,8,10,14-eicosatetraenoic acid. In agreement with 
the proposed structure the mass spectrum (fig.4) of 
the MesSi derivative the methyl ester of hydrogen- 
ated compound C (C-value 27.3) had prominent ions 
at m/e 575 (M-l 5), 559 (M-31), 489 (M-101), 469 
(M-(90 + 31)) 453,399 (M-(101 + 90)) 389 (M-201, 
loss of ‘CH2-(CH2)sCH20SiMes), 303 (MesSiO’= 
CH-(CH&-CH20SiMea), 299 (M-(201 + 90)) 203 
(base peak; see above), 129 and 103 (‘CHz=O’SiMea). 
Mass chromatogram of specific fragments generated 
by the computer [20], showed that the ion at 
m/e 103 (i.e., indicating an 01 hydroxyl group) 
appeared in a peak which cochromatographed with 
the total ion current of the pure compound. 
As shown in fig.5 the mass spectrum of the tri- 
methylsilyl ether methyl ester of hydrogenated com- 
pound A formed in ‘802-labeling experiments con- 
tained several ions that were shifted 4 units to higher 
m/e values (i.e., m/e 491,475,405 and 393) while 
other ions (i.e., m/e 313,301,217 and 205) were 
shifted 2 units to higher m/e values (cf., fig.3). These 
100 
2051 1217 
250 300 350 400 450 500 
m/e 
Fig.5. Mass spectrum of the Me,% derivative of the methyl ester of hydrogenated compound A formed in labeling experiments 
with “0 2’ 
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data show that compound A carried 2 atoms of 180, 
which were located at C-5 and C-12. The results dem- 
onstrate that the hydroxyl groups at C-5 and C-12 in 
compound A were both derived from molecular oxy- 
gen. The mass spectrum of the trimethylsilyl ether 
methyl ester of hydrogenated compound C from the 
180a-labeling experiments contained ions that were 
shifted to higher m/e values 6 units (i.e., m/e 581, 
565,495) 4 units (i.e., m/e 403,393,307) or 2 units 
(i.e., m/e 301,205 and 105). Thus, compound C car- 
ried 3 atoms of “0, showing that the hydroxyl 
groups of this compound were all derived from 
molecular oxygen. 
The (-)menthoxycarbonyl derivatives of the 
methyl esters of compounds A and C were subjected 
to oxidative ozonolysis and the fragments were 
treated with diazomethane prior to gas chromato- 
graphic analysis. The products from both compounds 
gave peaks corresponding to (-)-menthoxycarbonyl 
dimethyl S-malate and (-)-menthoxycarbonyl 
dimethyl 2-S-hydroxy adipate. These results demon- 
strate that the structures of compounds A and C are 
5S,12S-dihydroxy-6,8,10,14eicosatetraenoic acid 
and 5S,12S,20-trihydroxy-6,8,10,14eicosatetraenoic 
acid, respectively. 
Arachidonic acid 
/ 
\ 
&CM _ &H 
LTA4 SS-H(P)ETE H~DI~~cooH 
11 
*\ 
‘\ 
‘\ 12 S-H (PIETE 
‘\ I 
I 
I 
,t\*xx & 
COO” 
- 
LTB, 
6-tnns-LTB& and 
12-epi-6-tnns-LTB4 5S,12S-DHETE 
OH 
5S,12S, PO-THETE 
Fig.6. Scheme of transformation of arachidonic acid to SS,121idihydroxy-6,8,10,14~icosatetraenoic ac d and 5S,12+S-20-trihy- 
droxy6,8,10,14eicosatetraenoic acid by preparations of human polymorphonuclear leukocytes. Dashed lines indicate proposed 
reactions. 
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4. Discussion 
Here we describe the transformation of arachi- 
donic acid into a new leukotriene-like dihydroxy acid 
and a related trihydroxy acid in a preparation of 
human polymorphonuclear leukocytes. The structure 
of the novel dihydroxy acid is 5S,l2S-dihydroxy- 
6,8,10,14-eicosatetraenoic acid. In addition, an 
wl-hydroxylated metabolite, %,I 2S,20-trihydroxy- 
6,8,10,14eicosatetraenoic acid has been identified. 
Elucidation of the structures was based on chromato- 
graphic properties, UV-absorbance and GC/MS- 
analysis of various derivatives, including hydrogen- 
ated compounds. 
Oxidative ozonolysis of the (-)-menthoxycar- 
bony1 derivatives of compounds A and C supported 
the proposed locations of the 4 double bonds and 
made it possible to determine the absolute configura- 
tion of the alcohol groups at C-5 and C-12. The 
geometry of the double bonds has not yet been dem- 
onstrated. However, the chromatographic, W-absorb. 
ante and GC/MS data distinguish the new dihydroxy 
acid from the two C-12epimers of 5,12-dihydroxy- 
6,8,10,14-eicosatetraenoic acid [8] which both have 
an all-trans configuration of the triene. Therefore, the 
conjugated triene of the compound must contain at 
least one cis double bond since an all-trans geometry 
would make the new metabolite identical to 12-epi-6- 
truns-LTB,. Because of mass spectrometric similari- 
ties it is likely that compound C is formed from com- 
pound A via an w-oxidation and therefore has the 
same geometry of the double bonds. Labeling exper- 
iments with 1802 indicate that the compounds are 
formed by double and triple oxygenation of arachi- 
donic acid. Incorporation of molecular oxygen at C-5 
and C-l 2 of arachidonic acid in lipoxygenase cata- 
lyzed reactions should lead to isomerization of the 
double bonds cis-A5 and cis-A” to tram-A6 and 
trans-A”, respectively. Since the double bonds at A8 
and Al4 are not involved in these transformations 
they have probably retained their original cis con- 
figuration. Therefore, the geometry of the double 
bonds in both compounds is most likely 6-trans,8- 
cis,lO-trans,lcl-cis. 
Since the compounds are not formed from the 
unstable leukotriene epoxide (LT&) they are not 
regarded as leukotrienes. Instead, the trivial names 
5S,12S-DHETE and 5S,l2S,20-THETE are intro- 
duced. It has not been established whether the forma- 
tion of the compounds is initiated by oxygenation at 
334 
C-5 or C-l 2 (see figd). Leukocyte preparations are 
usually contaminated by platelets. Since the lipoxy- 
genase of these cells produce 12-SHETE [21], it is 
possible that the hydroxylation of C-l 2 occurs in the 
platelets while the hydroxylation at C-5 is carried out 
by the leukocytes. Control experiments with washed 
human platelets showed that 5S,l2S-DHETE or 
5SJ 2S,20-THETE could not be produced by plate- 
lets alone (not shown). Further investigations are 
required to determine the cellular origin of the new 
metabolites. 
Additional studies in progress indicate that 5S,l2S- 
DHETE and 5S,l2S,20-THETE are biologically active. 
These results will be reported separately. 
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